Clinical trial Recruiting at 1 site Observational Ages 18 and up

Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS

Official title: Myocardial Energetic Phenotyping and Prognostic Value Across the Cardiac Disease Spectrum: A 31P Magnetic Resonance Spectroscopy Study

Run by Chinese Academy of Medical Sciences, Fuwai Hospital · NCT07912086 · Data updated 2026-11-12

Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorChinese Academy of Medical Sciences, Fuwai Hospital
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedAugust 1, 2025
Main results expectedSeptember 1, 2030
Study endsSeptember 1, 2035
Registry record updatedNovember 3, 2026
Trial IDNCT07912086 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older, including healthy volunteers or patients with non-ischemic or ischemic cardiomyopathy, hypertensive or valvular heart disease, inflammatory or inherited metabolic cardiomyopathies, who can undergo CMR.

Probably not a fit

Patients unable to undergo CMR or without specific cardiomyopathy or heart failure phenotypes may receive limited or no direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll up to 1,000 participants, including healthy volunteers and patients with heart failure and a range of cardiomyopathies, to characterize myocardial energetic phenotypes. By combining 31P-MRS with multiparametric cardiac MRI, the study aims to define metabolic signatures that relate to structural changes and clinical biomarkers. The primary outcome is the myocardial PCr/ATP ratio, an in vivo marker of energetic impairment, with secondary exploration of relationships to remodeling and function. The trial is centered at the Chinese Academy of Medical Sciences and Fuwai Hospital in Beijing, led by a national sponsor.

Why it matters

Potential benefit: If successful, the study could identify metabolic markers that help classify cardiomyopathies and guide prognosis and individualized management.

How similar studies have gone: Previous pulse of work using 31P-MRS has shown feasibility in characterizing myocardial energetics, but this large, diverse cohort study is relatively novel in broad-spectrum phenotyping.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \>= 18 years
* Healthy volunteers, OR
* Clinical diagnosis of cardiac disease, including non-ischemic cardiomyopathy (hypertrophic, amyloid, or inflammatory), ischemic cardiomyopathy, hypertensive heart disease, or valvular heart disease, OR
* Inherited metabolic cardiomyopathies
* Able to undergo CMR examination and provide written informed consent

Exclusion Criteria:

\* Any contraindication to CMR examination

Where it's running

  • Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital
    Beijing, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.